In multiple myeloma (MM) increased numbers of monoclonal plasma cells in the bone marrow induce localized osteolytic lesions that rarely heal, due to increased bone resorption and suppressed bone formation. Numerous studies reported the contributions that different cell types in the MM microenvironment make to MM growth and bone disease, but the role of matrixembedded osteocytes in MM, which comprise >95% of bone cells and are major regulators of osteoclast and osteoblast activity, is unclear. We report that osteocytes in MM-bearing bones physically interact with MM cells in vivo, undergo caspase3-dependent apoptosis, and express higher RANKL and Sclerostin levels than osteocytes from control mice. Mechanistic studies revealed that osteocyte apoptosis is initiated by activation of Notch signaling in osteocytes through direct contact with MM cells, and is further amplified by MM cell-secreted TNFα. This Notch/ TNFα induced osteocyte apoptosis increases osteocytic Rankl expression, the osteocytic Rankl/Opg ratio and the ability of osteocytes to attract osteoclast precursors to induce local bone resorption. Further, osteocytes in contact with MM cells express high levels of Sost/Sclerostin that decrease Wnt signaling in osteoblasts and inhibit osteoblast differentiation. Importantly, direct contact between osteocytes and MM cells reciprocally activates Notch signaling and increases Notch receptor expression in MM cells, in particular Notch3 and 4, and stimulates MM cell 
Introduction
Multiple myeloma (MM) is characterized by expansion of monoclonal plasma cells in the bone marrow (BM) that induce marked bone destruction in the majority of patients (1) . MM patients present with severe bone pain caused by osteolytic lesions that rarely heal (2) . The osteolytic lesions result from increased bone resorption and concomitant long-term suppression of bone formation. The bone/BM microenvironment is a major contributor to tumor growth and bone destruction in MM (3) . The bone remodeling compartment is disrupted in MM allowing exchange of soluble factors and direct cell-to-cell contact between MM cells and bone cells (4) . Previous studies demonstrated that multiple cytokines are secreted or induced by the interaction of MM cells with the different cell types in the bone microenvironment to increase bone destruction, including the receptor of activator nuclear factor-kappa B ligand (RANKL), the chemokine (C-C motif) ligand 3 (MIP1α) and interleukin-3 (IL-3). Further, MM-derived interleukin 7 (IL-7), dickkopf WNT signaling pathway inhibitor 1 (DKK1) and IL-3, as well as direct contact by MM cells with osteoblasts inhibit osteoblast differentiation (1, 5) .
Although osteoclasts and osteoblasts remodel bone by resorbing or forming bone respectively, osteocytes, which constitute >95% of all bone cells, are the central regulators of these processes (6, 7) . Osteocytes, although buried within bone mineral, extensively communicate with each other and with cells on the bone surface and in the marrow via cytoplasmic projections that run along canaliculi and form the osteocyte network. This network allows cell-to-cell communication and distributes osteocyte-secreted molecules that regulate osteoblast and osteoclast function. Osteocytes are the primary producers of Sclerostin, the product of the Sost gene, a potent inhibitor of bone formation, and are a major source of RANKL, the central osteoclastogenic factor (8, 9) . Lack of Sclerostin increases osteoblast number and activity, and deletion of osteocytic RANKL inhibits osteoclast formation and bone resorption, demonstrating that osteocytes are key regulators of osteoblast and osteoclast activity (10) (11) (12) . Moreover, apoptotic osteocytes, which accumulate with skeletal disuse, glucocorticoid excess or estrogen deficiency, increase local bone resorption by attracting osteoclast precursors to particular areas of bone (6, 13) . Although knowledge of the role of osteocytes and the osteocytic network in bone homeostasis and common skeletal diseases has greatly increased, the contribution of osteocytes to the development and progression of cancer involving bone is just beginning to be defined.
Cell proliferation analysis
Viable cells were enumerated by trypan blue exclusion. Fluorescence emitted by 5TGM1-GFP cells was measured in a SpectraMaxi3 microplate reader (Molecular Devices, Sunnyvale, CA, USA), set at 485 nm/520 nm. 5TGM1-GFP cell numbers linearly correlated with fluorescent units (RFU) (Suppl. Figure 1A ).
Transfections
MLO-A5 cells were transiently transfected using Lipofectamine-Plus (Invitrogen) (23, 24) .
Gene expression analysis
mRNA expression was quantified as previously described (25) . Murine soluble RANKL, OPG or human TNFα were quantified by Enzyme-linked immunosorbent assays (ELISA, R&D systems) of culture supernatants.
Western blot analysis
The assays were performed as described previously (25) . Detailed descriptions of antibodies can be found in Supplementary Methods.
Osteoclast precursor migration
48h-CM from JJN3, MLO-A5, or from JJN3 and MLO-A5 co-cultured in direct contact was placed in the bottom of 8 μm pore chambers to attract murine non-adherent BM cells (26) . Detailed description of the assay can be found in Supplementary Methods.
Mouse model of human MM
6wk-old female SCID mice B6.CB17-Prkdcscid/SzJ (Jackson laboratories, Bar Harbor, Maine, USA) and NIH-Lyst bg Foxn1 nu Btk xid (Charles River Wilmington, Massachusetts, USA) were injected intratibially with JJN3 cells or saline and sacrificed 4wks later (16) . Detailed information regarding imaging and micro-CT analysis can be found in Supplementary Methods. Studies were approved by the Institutional Animal Care and Use Committee of the Indiana University School of Medicine. The sample size was calculated based on a previous study (16) .
pair-wise multiple comparisons using Student-Newman-Keuls method. Means ± standard deviation (SD) are reported. P values <0.05 were considered significant.
Results

MM cells increase osteocyte apoptosis and osteocytic RANKL and Sclerostin production in an in vivo model of MM bone disease
Our murine model of human MM is well-established and reproduces all features of human MM-induced bone disease (16) . Osteolytic lesions were first detected radiographically 2wks after JJN3 cell injection (Suppl. Figure 1B) and their size progressively increased up to 4wks ( Figure 1A) . Micro-CT analysis of JJN3-involved tibia performed at 4wks confirmed the presence of osteolytic lesions and demonstrated decreased trabecular bone volume (BV/TV), trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and increased trabecular separation (Tb.Sp.) compared to controls ( Figure 1B ). The percentage of apoptotic osteocytes, stained with an anti-active CASP3 antibody, was increased 2 fold in bones injected with JJN3 cells compared to controls ( Figure 1C) . Moreover, the percentage of osteocytes expressing RANKL and Sclerostin was significantly higher in JJN3-injected mice compared to controls. These findings suggest that in addition to survival, osteocyte gene expression is altered in MM-bearing bones. Histological analysis of MM bearing bones showed that MM cells were adjacent to the bone surface, and acid etching-SEM images revealed that osteocytic dendritic processes were in direct contact with MM cells in the marrow (Figures 1D and E) . Thus osteocytes are in close contact with MM cells, suggesting that MM-induced changes in osteocytes may result from cell-to-cell contact and/or exchange of soluble factors between osteocytes and MM cells. (Figure 2A ). Cell death was detected at 8h and progressively increased at 24 and 48h. To elucidate the effect of factors released by MM cells on osteocyte apoptosis, the cell types were separated by a porous membrane that prevents physical interactions and only allows exchange of soluble factors. Co-culture of JJN3 and MLO-A5 cells separated by transwell chambers did not increase cell death at 8 or 24h, but it did at 48h (1-3% vs 8-13%) ( Figure  2B ). These results suggest that different mechanisms mediate the early and late increases in osteocyte cell death induced by MM cells. Co-culture of MLO-A5 cells with JJN3 cells or JJN3-CM increased the percentage of MLO-A5 cells exhibiting chromatin condensation and nuclear fragmentation, sine qua non features of apoptosis (Figure 2A and B) . Moreover, osteocyte death was inhibited by the CASP3 inhibitor, DEVD, at all time-points confirming that it was due to apoptosis ( Figure 2A , 2B, and Suppl. Figure 1C ). Co-culture of MLO-A5 cells with CD138 + cells from 6 different MM patients (Figure 2A ) or conditioned media (CM) from CD138 + cells from a MM patient ( Figure 2B ) also increased MLO-A5 cell apoptosis. Similar results were obtained when MLO-A5 were co-cultured with human MM. 1s or murine 5TGM1 MM cells, or when MLO-Y4 cells, another murine osteocytic cell line, were co-cultured with JJN3 cells (Suppl. Figure 1D ). Notch signaling is activated by cell-to-cell contact and regulates cell proliferation and apoptosis in multiple cell types (28) . Further, Notch signaling is aberrantly activated in MM cells due to the over-expression of Notch receptors and ligands (29, 30) , demonstrating that MM cells are potential signalers as well as targets of Notch. We therefore assessed if direct interactions between MM cells and osteocytes activate Notch in these cells and the potential biological consequences. Direct contact of MLO-A5 cells with JJN3 MM cells activated Notch signaling in MLO-A5 cells, as shown by the increased expression of the Notch target gene hairy/enhancer-of-split related with YRPW motif 1 (Hey1) ( Figure 2C ) and hairy and enhancer of split 1 (Hes1), which persisted up to 48h (Suppl. Figure 1E ). JJN3 cell activation of osteocytic Notch signaling was suppressed by the Notch inhibitor GSIXX, confirming the specificity of the effect ( Figure 2C ). Hey1 expression was also increased in MLO-A5 cells co-cultured with CD138 + cells from 3 of 5 MM patients ( Figure 2C ). As expected, Notch activation (Hey1 and Hes1) in osteocytes did not occur when MLO-A5 cells were co-cultured with MM cells in transwell chambers (Suppl. Figure 1F ). MM1.s or 5TGM1 MM cells also increased the Notch target gene expression in osteocyte-like MLO-A5 or MLO-Y4 cells (Suppl. Figure 1F ). In addition, interactions with JJN3 cells rapidly upregulated the expression of receptors Notch3 and Notch4 in MLO-A5 cells, whereas Notch1 or Notch2 receptor expression was unchanged ( Figure 2D ). Moreover, the levels of NOTCH3 and of NICD3, the active form and downstream effector of the receptor Notch3, were elevated in tumor-bearing bones compared to control bones, demonstrating that Notch signaling activation also occurs in vivo ( Figure 2E and F).
To evaluate the potential impact of gain-of-function of Notch signaling on osteocyte life span, MLO-A5 cells were transfected with nGFP and the Notch intracellular domains (NICD) 1 or 2, which translocate to the nucleus and activate Notch target gene transcription. Cells expressing either NICD1 or NICD2 exhibited increased apoptosis compared to vector controls ( Figure 3A) . Moreover, MLO-A5 cells cultured on plates coated with the Notch ligand DLL1 expressed higher levels of Hes1, confirming Notch activation, and had increased cell death (2-to 5-fold) compared to control cells cultured on IgG2 (1-2% vs 5-9% in control vs DLL1 treated cells). DLL1-induced death was completely inhibited by the Notch inhibitor GSIXX or by DEVD ( Figure 3B ), indicating that Notch activation is sufficient to trigger osteocyte apoptosis. Consistent with this observation, GSIXX completely blocked osteocytic cell death induced by direct co-culture with JJN3 cells or CD138 + cells from a MM patient at 8h or 24h ( Figure 3C ). In contrast, GSIXX only partially prevented MLO-A5 cell death measured at 48h, suggesting that factors secreted by MM cells accumulated during culture contribute to osteocyte apoptosis at later time points. In support of this notion, levels of TNFα, a recognized inducer of osteoblast and osteocyte apoptosis (31), increased 4-fold from 4 to 48h in CM from JJN3 cell cultures ( Figure 3D ), and addition of TNFα increased MLO-A5 cell death (Suppl. Figure 1G ). Consistent with a role for MM-secreted TNFα in MM-induced osteocyte apoptosis, the decrease in osteocyte viability induced by JJN3-CM was blocked by DEVD or by a neutralizing anti-human TNFα antibody, but not by GSIXX ( Figure 3D ). Moreover, GSIXX or anti-TNFα only partially inhibited cell death, whereas the combination of both completely blocked the increase in osteocytic cell death induced by direct co-culture of MLO-A5 cells with JJN3 cells for 48h ( Figure 3E ). These findings suggest that MM cells induce osteocyte apoptosis by activating Notch and TNFα signaling pathways in osteocytes.
Osteocyte apoptosis increases the osteoclastogenic potential of osteocytes and stimulates osteoclast precursor recruitment
We then investigated the consequences of osteocyte apoptosis on the osteoclastogenic potential of osteocytes. MLO-A5 cells co-cultured with JJN3 MM cells exhibited increased Rankl expression at the mRNA and protein levels ( Figure 4A We next determined the effect of osteocyte apoptosis on osteoclast precursor recruitment. CM from MLO-A5 cells cultured alone significantly increased osteoclast precursor migration compared to control media, whereas CM from JJN3 cells did not ( Figure 4C ). CM from JJN3 and MLO-A5 cells co-cultured in direct contact enhanced osteoclast precursor chemotaxis by 50% compared to CM from MLO-A5 cultured alone. This effect was inhibited by blocking osteocyte apoptosis with DEVD or by the combination of GSIXX and anti-TNFα. Taken together, these results suggest that MM-induced osteocyte apoptosis, even when modest, is sufficient to increase osteocytic Rankl expression and potentiate osteocyte-mediated recruitment of osteoclast precursors.
MM cells upregulate Sost expression in osteocytes, decrease Wnt signaling and inhibit osteoblast differentiation
Consistent with the increased Sclerostin expression in osteocytes in the in vivo MM mouse model, direct co-culture with JJN3 MM cells up-regulated Sost mRNA expression in MLO-A5 cells by 3-fold as early as 4h ( Figure 5A ), which remained elevated up to 24h (Suppl. Figure 2C ). Simultaneously with Sost upregulation, the expression of osteoprotegerin (Opg), a Wnt target gene, was decreased by 50%, both at mRNA ( Figure 5A ) and protein level (Suppl. Figure 2D) . Similarly, the mRNA levels of the other Wnt target genes Axin2 and Smad family member 6 (Smad6) (25, 33, 34) were also decreased. In contrast, Sost/Wnt target gene expression was not altered when MM and MLO-A5 cells were not in direct cell-to-cell contact. Sost upregulation induced by MM cells was also recapitulated in a three dimensional ex vivo bone organ model containing authentic osteocytes ( Figure 5B ). These findings suggest that interactions between osteocytes and MM cells upregulate the expression of Sost in osteocytes, which in turn decreases Wnt signaling.
We next examined the consequences of MM-induced upregulation of osteocytic Sost/ Sclerostin on osteoblast differentiation. Wnt/β catenin signaling is critical for osteoblast differentiation and this pathway is tightly regulated by pre-receptor antagonists, including the potent osteoblast inhibitor Sclerostin secreted by osteocytes (35) . CM from MLO-A5 cells co-cultured with JJN3 MM cells in direct contact markedly decreased the expression of the osteoblast markers alkaline phosphatase (Alp), collagen 1a (Col1a), runt related transcription factor 2 (Runx2) and bone gamma carboxyglutamate protein (Bglap) in OB-6 osteoblastic cells cultured under osteogenic conditions ( Figure 5C ). Expression of the Wnt target genes Axin2 and Smad6 was also significantly decreased by CM from MLO-A5-JJN3 co-cultures. The expression of these genes was unchanged by treatment with CM from MLO-A5 or JJN3 cells cultured separately.
Taken together, these results demonstrate that direct interactions between osteocytes and MM cells increase expression of Sost/Sclerostin in osteocytes, decrease Wnt signaling/β catenin and inhibit osteoblast differentiation.
Osteocytes activate Notch signaling to increase MM cell proliferation, and alter the Notch receptor repertoire in MM cells
Because Notch signaling can be bidirectional, we next examined if osteocytes modulate Notch signaling in MM cells. Co-culture of 5TGM1 cells in direct contact with MLO-A5 cells for 4h increased Hes1 and Hey1 expression by 2-4 fold in MM cells compared to MM cells cultured alone ( Figure 6A ). Similar upregulation in Hes1 expression was found in CD138 + cells from 3 of 4 MM patients examined ( Figure 6A and E) and in 5TGM1 cells cocultured in direct contact with MLO-Y4 cells (Suppl. Figure 3A) . GSIXX blocked the osteocyte-induced upregulation of Hes1 and Hey1 in 5TGM1 cells ( Figure 6B ). These results indicate that osteocytes activate Notch signaling in MM cells.
Co-culture of 5TGM1 cells in direct contact with MLO-A5 cells markedly increased the proliferation of 5TGM1 cells in a time-dependent manner ( Figure 6C ), whereas no changes were observed when cells were co-cultured without direct contact (Suppl. Figure 3B) . Further, inhibition of Notch signaling with GSIXX prevented in a dose-dependent manner the increased proliferation of 5TGM1 cells and CD138 + cell from a MM patient induced by MLO-A5 cells ( Figure 6C and E). Higher doses of GSIXX also inhibited proliferation of 5TGM1 cells cultured alone at 48h, and all doses were inhibitory at 72h of culture ( Figure  6C ).
Osteocyte-like MLO-A5 cells did not activate Notch signaling in all MM cells tested. Thus, MLO-A5 cells did not increase Notch target gene expression or stimulate MM cell proliferation in 1 of 4 CD138 + cell preparations from MM patients (Figure 6F ), or in MM1.s or JJN3 MM (Suppl. Figure 3C ). We next examined whether differences in proliferative responses of MM cells to osteocytes were due to differences in their Notch receptor repertoire. 5TGM1 cells, which readily respond to osteocytic cell interactions by activating Notch, express higher Notch3 levels (20-fold), and lower Notch1 and 2 compared to JJN3 cells in which osteocytic interactions do not activate Notch (Suppl. Figure 3D) . None of the MM cell lines expressed detectable levels of Notch4 when cultured alone. These results show that different MM cells express different levels of Notch receptors, and suggest that osteocytes may activate Notch signaling in MM cells through Notch3, leading to increased MM cell proliferation. Moreover, osteocytic interactions rapidly upregulated Notch3 expression in 5TGM1 cells and induced the expression of Notch4, which is undetectable in MM cells cultured alone ( Figure 6D) . Further, culture of 5TGM1 MM cells with authentic osteocytes in ex vivo bone organ cultures activated Notch signaling and increased the expression of Notch3 and 4 without altering Notch1 or 2 mRNA levels ( Figure 6G) . Similarly, CD138 + cells from a MM patient that exhibit Notch activation induced by osteocytes also displayed upregulation of Notch3 ( Figure 6E ), whereas no changes were found in other Notch receptors. In contrast, no changes in the expression of Notch3 were observed in CD138 + cells from a MM patient that did not show activation of Notch signaling after contact with MLO-A5 cells ( Figure 6F ). MLO-A5 cells also upregulated Notch1 and 2 in 5TGM1 cells at later time points ( Figure 6D ). These results demonstrate that osteocytes change the Notch receptor repertoire expressed by MM cells. Thus, the capacity of osteocytes to alter the Notch receptor repertoire on MM cells may regulate osteocyte enhancement of MM cell growth.
Discussion
Osteocytes play a central role in bone homeostasis by regulating osteoclast and osteoblast activity, and premature death of osteocytes leads to targeted bone resorption during skeletal disuse and estrogen loss (6) . We report that osteocytes also contribute to a microenvironment favorable for the progression of MM and its associated bone disease. First, we show that osteocytes physically interact with MM tumors in vivo which increases Sclerostin and RANKL production by osteocytes, and reduces osteocyte viability. Second, the reduced viability of osteocytes is due to apoptosis triggered by MM cell-mediated activation of Notch signaling and sustained by MM-derived TNFα. Third, elevated osteocyte apoptosis increases osteocytic Rankl expression and enhances the ability of osteocytes to attract osteoclast precursors. Fourth, the increase in Sost/Sclerostin decreases Wnt signaling and inhibits osteoblast differentiation. Fifth, osteocytes induce reciprocal activation of Notch signaling in MM cells, which in turn enhances MM cell proliferation, and alters the Notch receptor repertoire on MM cells. Importantly, these results were validated in in vivo and in vitro, as well as in a novel ex vivo model, using several MM cell lines and CD138 + cells from MM patients. Taken together, these findings demonstrate that interactions between MM cells and osteocytes within the bone/BM microenvironment generate a permissive niche for MM cell growth and bone destruction (Figure 7) . Thus, targeting osteocytes and their derived factors might represent a novel approach to treat MM bone disease.
Consistent with our findings showing that osteocytes induce MM cell growth by activating Notch signaling, several studies have shown that dysregulation of Notch signaling increases MM growth (36) (37) (38) , and paracrine Notch activation mediated by BM stromal cells increases MM cell proliferation, through NOTCH1 and 2 signaling (30, 39, 40) . However, Notch3 and 4 appear to mediate the osteocytic effects, suggesting that regulation of Notch activation in MM is mediated by complex paracrine interactions with different cell types within the bone/BM microenvironment. Further, the changes in the Notch receptor repertoire on MM cells induced by osteocytic interactions could impact both the homotypic and heterotypic cell-to-cell interactions of MM cells. Although the specific roles of Notch3 and 4 in MM are not fully understood, selective Notch receptor targeting may allow control of MM cell growth and its associated bone disease. Future studies to investigate this possibility and to identify relevant Notch ligands on osteocytes are warranted.
The increased prevalence of osteocyte apoptosis observed in our in vivo model is consistent with a previous report in bone biopsies from MM patients (17) , although the mechanism of this phenomenon was not addressed. We show here that osteocyte apoptosis induced by MM cells is triggered by activation of Notch signaling followed by induction of the caspase cascade, and maintained by MM-cell derived TNFα. However, Giuliani et al were unable to block osteocyte apoptosis by neutralizing TNFα (17) . This discrepancy, together with their inability to detect changes in osteocytic RANKL, could be explained by the use of cells lines at different stages of differentiation of the osteoblastic lineage. We used the late osteoblast/ early osteocyte-like MLO-A5 cell line that expresses the recognized osteocytic genes Sost/ Sclerostin and Rankl, whereas the HOB-01 pre-osteocytic cells used in the Giuliani study do not. Moreover, we validated our in vivo observations and mechanistic studies using MLO-Y4 cells, an additional osteocytic cell line widely used as an osteocyte model, and confirmed our findings in authentic osteocytes using ex vivo bone organ cultures. Our results demonstrate that murine and human MM cell lines and CD138 + from MM patients act as Notch signalers in osteocytes that concurrently with MM-secreted TNFα induce osteocyte apoptosis.
Although our current findings demonstrating different outcomes of Notch activation in MM cells (proliferation) versus in osteocytes (apoptosis) may appear counterintuitive, they are consistent with earlier studies showing the cell type-and context-dependent nature of Notch signaling. Thus, whereas activation of Notch signaling protects several cancer cell types from apoptosis (36, 41) , it induces apoptosis of neural progenitor cells (42) , CD34 + hematopoietic stem/progenitor cells (43) , and osteocytes (this report). Similarly, activation of canonical Wnt signaling inhibits apoptosis in different cells of the osteoblastic lineage (31, 44) , whereas it increases apoptosis in hematopoietic stem/progenitor cells (45) or in melanoma cells (46) . These findings show that the same signaling pathway can elicit different biological responses depending on the ligands/signals present in a particular microenvironment, the receptor repertoire exhibited by the target cell, and the intracellular machinery that integrates extracellular cues and transduces them into biological outcomes.
Osteocyte-derived interleukin 11 has been shown to contribute to osteoclast differentiation in MM (17) . We show that apoptotic osteocytes attract osteoclast precursors more potently than MM cells in our in vitro system. Further, although relatively modest, the increased osteocyte apoptosis was sufficient to upregulate osteocyte Rankl. These findings suggest that similar to other pathological conditions, MM-induced osteocyte apoptosis plays a central role in osteoclast recruitment and may initiate and/or sustain bone resorption within the focal lesions observed in MM patients. Further studies are warranted to determine whether osteocyte apoptosis leads to osteoclast differentiation in MM and to identify the molecular mediators.
Sclerostin levels are elevated in the sera of MM patients and correlate with reduced osteoblast function and poor patient survival (47) . However, the source of Sclerostin remains unclear. CD138 + cells from MM patients were reported to express Sclerostin (48); but we could not detect Sost mRNA in any patient CD138 + cells studied. In contrast, our in vitro and in vivo models demonstrate that Sost/Sclerostin expression is elevated in osteocytes. Further, Sost/Sclerostin upregulation in osteocytes was associated with decreased Wnt signaling in osteoblasts and reduced osteoblast differentiation. In addition, the expression of Wnt target genes, including OPG, was reduced; thereby further increasing the Rankl/Opg ratio. These results suggest that osteocytes contribute to the generation of a MM microenvironment with high Sclerostin concentrations, affecting both bone formation and bone resorption.
Physical interactions between MM cells and different cells in the bone microenvironment, including stromal cells, osteoclasts and immune cells, were shown to be important for tumor proliferation and survival (49) . Our results suggest that osteocytes also contribute to MM cell growth and MM induced bone disease by stimulating osteoclast recruitment and inhibiting bone formation via direct and indirect contact with MM cells. Since osteocytes comprise more than 95% of the bone cells, they should be major contributors to generating a microenvironment favorable for MM progression. However, the relative contribution of osteocytes versus other cell types in the bone/BM microenvironment to MM disease remains to be determined.
Our study identified pathways activated by interactions between MM cells and osteocytes that provide potential new ways to inhibit MM tumor growth and bone disease. Prevention of osteocyte apoptosis might suppress initiation of bone resorption by inhibiting osteoclast recruitment as well as improving the bone fragility syndrome associated with MM and with some of the current anti-tumor drugs (eg. glucocorticoids that also increase osteocyte apoptosis). Pharmacological inhibition of Notch signaling can inhibit MM cell growth (50, 51) and could provide additional benefits by inhibiting osteocyte apoptosis, either alone or in combination with TNFα signaling blockade. Our findings demonstrate that osteocytes regulate the expression and repertoire of Notch receptors on MM cells, supporting development of therapeutic approaches that block specific Notch receptors. This approach might be an effective alternative to overcome the side-effects associated with generalized Notch inhibition (36) .
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